De novohepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody

• DOI: 10.4174/astr.2015.89.3.145
• Publication Date: 2015-09-02T23:44:39Z
• Authors: Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You; Jong Young Choi; Seung Kew Yoon
• Keywords: Entecavir; Seroconversion; Hepatitis B

The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where endemic. However, this remains controversial because the risk development de novo HBV infection.We collected information obtained between January 2000 and December 2012 retrospectively analyzed data on 187 HBsAg-negative donors recipients were retrospectively. De infection was defined as HBsAg positivity with or without detection DNA.Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). occurred in five (12.5%) who treated anti-HBV prophylaxis, significantly more prevalent surface (HBsAb)- HBcAb-negative than HBsAb- (50% vs. 4.2%, P 0.049). All except one entecavir with/without antihepatitis immunoglobulin four negative terms DNA seroconversion. No patient died.HBcAb-positive are safe survival difference. virus increased recipients. successfully even after recurrence.